Full Year 2017 Financial Results:
|●||Revenue of $31.8 million for the year, 30% growth over 2016|
|●||GAAP net loss of $5.6 million, an improvement of $3.2 million from 2016|
|●||Adjusted EBITDA of $2.3 million or 7.2% of revenue for the year, a new record|
|●||Adjusted net income of $36,000, an improvement of $2.0 million from 2016|
|●||GAAP operating loss of $4.5 million, an improvement of $3.4 million from 2016|
|●||Adjusted operating income of $1.3 million, a new record|
Fourth Quarter 2017 Financial Results:
|●||Revenue of $8.3 million for fourth quarter 2017|
|●||GAAP net loss of $184,000, an improvement of $3.8 million from Q4 2016|
|●||Adjusted EBITDA of $1.5 million or 18% of revenue, a new record|
|●||Adjusted net income of $1.3 million or $0.13 per share, a new record|
|●||GAAP operating loss of $454,000|
|●||Adjusted operating income of $1.4 million or 16% of revenue, a new record|
SOMERSET, N.J., March 07, 2018 (GLOBE NEWSWIRE) — MTBC (the “Company” or “MTBC”) (NASDAQ:MTBC) (NASDAQ:MTBCP), a leading provider of proprietary, cloud-based healthcare IT solutions and services, today announced financial and operational results for year 2017. The Company’s management will conduct a conference call later today at 8:30 a.m. Eastern Time to discuss these results and management’s outlook for future financial and operational performance.
“I am thrilled to report a strong finish to the year, with revenue growth of 30% over 2016 and record adjusted EBITDA of $2.3 million,” said Mahmud Haq, MTBC’s Executive Chairman. “In addition to significant revenue growth and profit improvement, our balance sheet has never been stronger,” he continued. “We ended 2017 with $4.4 million of cash and virtually no debt, having fully repaid our $10 million credit facility with Opus Bank two years prior to the original maturity date, paid Prudential the remaining purchase price of $5 million plus interest related to the MediGain transaction, and secured a $5 million line of credit from Silicon Valley Bank, which was untapped on December 31, 2017.
Stephen Snyder, MTBC’s Chief Executive Officer said, “2017 was a landmark year for us, allowing us to dramatically reduce costs and begin generating positive cash flow at the same time we raised the capital which allowed us to end the year virtually debt free.”
“During the year, we have seen more signs that the industry is consolidating. EHR companies are finding it harder to generate enough value for clients without an integrated revenue cycle management offering, and RCM companies are finding it harder to operate profitably without their own technology platform and low-cost offshore teams,” said A. Hadi Chaudhry, MTBC’s President. He continued, “these trends create a great opportunity for us to partner with others in the industry, and with our strong capital position, might provide an opportunity for significant acquisitions at values that are accretive to shareholders.”
Full year 2017 financial results
Revenues for full year 2017 were $31.8 million, an increase of 30% compared to $24.5 million last year. The increase was primarily due to the MediGain transaction. Revenue exceeded the midpoint of our upward adjusted guidance, which was a range of $31 to $32 million.
For the full year of 2017, the GAAP net loss was $5.6 million, which was largely a result of non-cash amortization and depreciation expense of $4.3 million. This reflected an improvement of $3.2 million compared to the prior year. “We saw steady improvement in our GAAP net loss for each of the last 4 quarters, as we reduced expenses which arose from our acquisition of the assets of MediGain in October 2016,” said Bill Korn, Chief Financial Officer. “The significant cost savings we have achieved included reducing reliance on subcontractors, reducing fees paid to third party software vendors, reducing U.S. facility and personnel costs, closing offices in Poland and Bangalore, India, and improving operating efficiencies.”
The GAAP net loss for 2017 was $0.69 per share, calculated using the net loss attributable to common shareholders divided by the weighted average number of common shares outstanding.
Adjusted EBITDA for the full year of 2017 was $2.3 million, or 7.2% of revenue, an improvement of $2.9 million from compared to adjusted EBITDA of ($605,000) in 2016. Adjusted EBITDA exceeded the midpoint of our guidance, which was a range of $2.0 to $2.5 million, and represents the highest adjusted EBITDA MTBC has achieved in its 15-year history. Bill Korn commented, “Our business now has a higher scale than we did during most of 2016, so we are able to spread our fixed expenses over a larger revenue base and generate larger adjusted EBITDA than we ever have before.”
“The difference of $7.9 million between adjusted EBITDA and the GAAP net loss in 2017 reflects $4.3 million of non-cash amortization and depreciation expense, $1.3 million of net interest expense, $1.5 million of stock-based compensation, $791,000 of integration, transaction and restructuring costs related to recent acquisitions, and a $68,000 provision for income taxes,” said Bill Korn.
Non-GAAP adjusted net income for 2017 was $36,000, or $0.00 per share, an improvement of $2.0 million compared to last year. Non-GAAP adjusted net income per share is calculated using the end-of-period common shares outstanding. “Non-GAAP adjusted net income excludes $3.4 million of non-cash amortization of purchased intangible assets, $1.5 million of stock-based compensation, $791,000 of integration, transaction and restructuring costs and $249,000 of foreign exchange gains,” said Bill Korn.
The 2017 GAAP operating loss was $4.5 million, which represents an improvement of $3.4 million or 43% from the operating loss in 2016. GAAP operating loss excludes the provision for income taxes, net interest expense and other income and expenses, which are included in the GAAP net loss.
Non-GAAP adjusted operating income was $1.3 million, or 4.1% of revenue, which represents an improvement of $2.6 million from 2016. “This is our third consecutive quarter of positive non-GAAP adjusted operating income, which excludes non-cash expenses such as $3.4 million of purchased intangible assets, $1.5 million of stock-based compensation and $791,000 of integration, transaction and restructuring costs,” said Bill Korn.
Fourth quarter 2017 financial results
Revenues for fourth quarter 2017 were $8.3 million, compared to $8.8 million in the same period last year. Fourth quarter 2016 revenue included residual revenue from certain MediGain clients who we knew had decided not to continue prior to the closing of our transaction in October 2016. We were able to turn around MediGain’s largest client, who prior to our acquisition had given indication that they were prepared to terminate services. They are pleased with our performance and were our largest revenue-generating client in 2017.
The fourth quarter 2017 GAAP net loss was $184,000, or 2.2% of revenue, an improvement of $3.8 million compared to a net loss of $4.0 million in fourth quarter of 2016. “The dramatic reduction in our GAAP net loss was due to a $2.0 million or 33% reduction in direct operating costs, a $781,000 or 18% reduction in general & administrative expense and a $908,000 reduction in depreciation & amortization expenses compared with fourth quarter 2016,” said Bill Korn.
The GAAP net loss for fourth quarter 2017 was $0.08 per share, calculated using the net loss attributable to common shareholders divided by the weighted average number of common shares outstanding.
Adjusted EBITDA for fourth quarter 2017 was $1.5 million, or 18% of revenue, compared to adjusted EBITDA of ($814,000), or (9.2%) of revenue, in the same period last year. “The fourth quarter 2017 adjusted EBITDA represents an improvement of $2.3 million from the same period last year, reflecting the significant cost savings we have achieved,” continued Bill Korn.
“The difference of $1.7 million between adjusted EBITDA and the GAAP net loss in the fourth quarter of 2017 reflects $663,000 of non-cash amortization and depreciation expense, $78,000 of net interest expense, $1.2 million of stock-based compensation, $155,000 of integration and transaction costs, and $124,000 of benefit for income taxes,” said Bill Korn.
Non-GAAP adjusted net income for fourth quarter 2017 was $1.3 million, or $0.13 per share, compared to the adjusted net income of ($1.3 million) in the same period last year. Non-GAAP adjusted net income per share is calculated using the end-of-period common shares outstanding. This is the Company’s best quarter of adjusted net income in our history.
The fourth quarter 2017 GAAP operating loss was $454,000, which represents an improvement of $3.3 million from fourth quarter of 2016.
Non-GAAP adjusted operating income for fourth quarter 2017 was $1.4 million, or 16% of revenue. “The fourth quarter 2017 adjusted operating income represents an improvement of $1.0 million from the adjusted operating income in third quarter 2017 and an improvement of $2.4 million from fourth quarter 2016,” continued Bill Korn. “This is our third consecutive quarter of positive non-GAAP adjusted operating income, and reflects the fact that our business is now at a scale where our revenues are exceeding our cash operating expenses quarter after quarter.”
In fourth quarter 2017, cash flow from operations was $1.6 million, and for the full year, cash flow from operations was $282,000.
Cash Balance and Capital
As of December 31, 2017, the Company had $4.4 million in cash and positive working capital of approximately $4.6 million, a $12.0 million improvement from the working capital deficiency of approximately $7.4 million reported at the end of the year 2016.
The Company raised net proceeds of $16.5 million from the sale of approximately 765,000 additional shares of its non-convertible Series A Preferred Stock via six small public offerings during 2017, as well as net proceeds of $2 million from a registered direct sale of 1 million shares of common stock in May 2017. The preferred shares trade on the Nasdaq Capital Market under the ticker MTBCP, and pay monthly cash dividends at the rate of 11% per annum.
According to Bill Korn, “The cash cost of our dividends is far less than what most businesses pay for term debt, which is typically repaid over three or four years. Typically 25% or 33% of the value of debt is spent annually to repay principal, on top of the interest rate. Our Series A Preferred Stock is perpetual, and has no mandatory redemption, although the Company can choose to redeem shares at $25.00 per share starting in November 2020, so our 11% cost is lower than the typical cash outlay.”
The Company used a portion of the net proceeds of these offerings to repay in full its term loans and line of credit with Opus, which totaled approximately $9.3 million as of December 31, 2016. In addition, the Company paid Prudential approximately $5.3 million, which covered the remainder of the purchase price related to the MediGain transaction, plus interest.
During early October, the Company entered into a new revolving credit facility with Silicon Valley Bank (“SVB”), and repaid and terminated its previous revolving credit facility with Opus. The SVB credit facility is a $5 million secured revolving line of credit where borrowings are based on a formula of 200% of repeatable revenue adjusted by an annualized attrition rate as defined in the agreement. While there was nothing drawn on the SVB credit facility at year-end 2017, and nothing as of today, the SVB line can be used for future growth initiatives, including acquisitions with SVB’s approval.
According to Bill Korn, “based on MTBC’s current financial position, with net losses significantly lower than last year, adjusted net income and adjusted EBITDA that are positive, and cash flow from operations that is positive, the Company was able to remove the ‘going concern’ disclosure included in last year’s 10-K. We now have a solid financial foundation, which leaves the Company well-positioned for growth. We have more capital available now than at any time in the Company’s history, and see exciting opportunities to profit from the continued consolidation of the industry.”
Bill Korn continued, “In 2018, we have three paths for continued growth, including organic growth, partnership opportunities, and the potential for an accretive acquisition which might be material. We are pursuing all three of these in parallel. Unlike past years, today we can point to our recent results rather than simply expectations for the future. We anticipate spending more on sales and marketing in 2018 than the 3.5% of revenue we spent in 2017, but we are confident that we will be able to report significant growth in our adjusted EBITDA in 2018. Other metrics may change, and the exact revenue and the quarterly numbers will depending on the actual opportunities we close and the timing. As a result, the Company has decided not to provide detailed forward-looking guidance at this time.”
Conference Call Information
MTBC management will host a conference call today at 8:30 a.m. Eastern Time to discuss the 2017 results. The live webcast of the conference call can be accessed under Events & Presentations at ir.mtbc.com or by dialing 412-317-5131 and referencing “MTBC Full Year and Fourth Quarter 2017 Earnings Call.”
A replay of the conference call will be available approximately one hour after conclusion of the call at the same link. An audio replay can also be accessed by dialing 412-317-0088 and providing access code 10116612.
MTBC is a healthcare information technology company that provides a fully integrated suite of proprietary web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. Our integrated Software-as-a-Service (or SaaS) platform helps our customers increase revenues, streamline workflows and make better business and clinical decisions, while reducing administrative burdens and operating costs. MTBC’s common stock trades on the NASDAQ Capital Market under the ticker symbol “MTBC,” and its Series A Preferred Stock trades on the NASDAQ Capital Market under the ticker symbol “MTBCP.”
For additional information, please visit our website at www.mtbc.com.
PracticePro™, talkEHR™ and EnrollmentPlus™ are trademarks of MTBC.
Use of Non-GAAP Financial Measures
In our earnings releases, prepared remarks, conference calls, slide presentations, and webcasts, we may use or discuss non-GAAP financial measures, as defined by SEC Regulation G. The GAAP financial measure most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measure, are included in this press release after the condensed consolidated financial statements. Our earnings press releases containing such non-GAAP reconciliations can be found in the Investor Relations section of our web site at ir.mtbc.com.
This press release contains various forward-looking statements within the meaning of the federal securities laws. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “might,” “will,” “should,” “intends,” “expects,” “plans,” “goals,” “projects,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of these terms or other comparable terminology.
Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. Forward-looking statements in this press release include, without limitation, statements reflecting management’s expectations for future financial performance and operating expenditures, expected growth, profitability and business outlook, increased sales and marketing expenses, and the expected results from the integration of our acquisitions.
These forward-looking statements are only predictions, are uncertain and involve substantial known and unknown risks, uncertainties and other factors which may cause our (or our industry’s) actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all of the risks and uncertainties that could have an impact on the forward-looking statements, including without limitation, risks and uncertainties relating to the Company’s ability to manage growth, migrate newly acquired customers and retain new and existing customers, maintain cost-effective operations in Pakistan and Sri Lanka, increase operational efficiency and reduce operating costs, predict and properly adjust to changes in reimbursement and other industry regulations and trends, retain the services of key personnel, and other important risks and uncertainties referenced and discussed under the heading titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission.
The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not assume any obligations to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.
Tailwinds’ Disclaimers & Disclosures: For a full list of disclaimers and disclosures, please visit: www.tailwindsresearch.com/disclaimer/Tailwinds' Disclaimers & Disclosures: For a full list of disclaimers and disclosures, please visit http://